GlassScriptPhysician profile
Mason D Devon
NPI 1235492299
$793.93
in general payments reported to CMS, 2019-2025
12 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2023: $87.59 · 2024: $205 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.26 | 2021-2024 | Andexxa |
| Stryker Corporation | $170.36 | 2021 | |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Abbvie INC. | $101.91 | 2024-2025 | |
| Tersera Therapeutics LLC | $35.93 | 2025 | Zoladex |
| Catalyst Pharmaceuticals, INC. | $31.73 | 2023 | Firdapse |
| Vertex Pharmaceuticals Incorporated | $29.46 | 2025 | |
| Urogen Pharma, INC. | $28.97 | 2024 | |
| Genentech USA, INC. | $19.38 | 2024 | Herceptin, Itovebi, Tecentriq Hybreza |
| Merck Sharp & Dohme LLC | $16.95 | 2024 | Keytruda |
| Eisai INC. | $15.27 | 2024 | |
| Caris Mpi, INC. | $15.14 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Devon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.